Tech Company Financing Transactions
Jounce Therapeutics Funding Round
On 2/14/2013, Jounce Therapeutics raised $47 million in Series A financing from Third Rock Ventures.
Transaction Overview
Company Name
Announced On
2/14/2013
Transaction Type
Venture Equity
Amount
$47,000,000
Round
Series A
Investors
Third Rock Ventures (Cary Pfeffer)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
780 Memorial Dr.
Cambridge, MA 02138
USA
Cambridge, MA 02138
USA
Phone
Website
Email Address
Not Recorded
Overview
Jounce Therapeutics (NASDAQ: JNCE) is focused on the discovery and development of first-in-class cancer immunotherapies designed to work not by treating a patient's tumor directly, but instead by harnessing the patient's immune system to seek out and attack cancerous cells and tumors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Richard Murray
Chief Financial Officer
Kim Drapkin
Chief Medical Officer
Elizabeth Trehu
Chief Technical Officer
Stephen Farrand
VP - Bus. Development
Hugh Cole
VP - Human Resources
Ted Harding
VP - Regulatory Affairs
Allison Nance
Browse more venture capital transactions:
Prev: 2/14/2013: X2 Biosystems venture capital transaction
Next: 2/15/2013: Vorago Technologies venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs